SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001140361-23-052753
Filing Date
2023-11-13
Accepted
2023-11-13 09:21:40
Documents
14
Period of Report
2023-08-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A ef20014607_8ka.htm   iXBRL 8-K/A 30238
2 EXHIBIT 99.1 ef20014607_ex99-1.htm EX-99.1 102153
6 image00001.jpg GRAPHIC 5266
  Complete submission text file 0001140361-23-052753.txt   288951

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA galt-20230814.xsd EX-101.SCH 3901
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE galt-20230814_lab.xml EX-101.LAB 22546
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE galt-20230814_pre.xml EX-101.PRE 16068
8 EXTRACTED XBRL INSTANCE DOCUMENT ef20014607_8ka_htm.xml XML 4246
Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

IRS No.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-31791 | Film No.: 231395769
SIC: 2834 Pharmaceutical Preparations